D. Symmons, What is rheumatoid arthritis, Br Med Bull, vol.51, pp.243-248, 1995.

P. K. Gregersen, J. Silver, and R. J. Winchester, The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis, Arthritis Rheum, vol.30, pp.1205-1213, 1987.

W. Ollier and W. Thomson, Population genetics of rheumatoid arthritis, Rheum Dis Clin North Am, vol.18, pp.741-759, 1992.

N. Balandraud, HLA-DRB1 genotypes and the risk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis, PLoS One, vol.8, p.64108, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02440894

G. A. Schellekens, B. A. De-jong, F. H. Van-den-hoogen, L. B. Van-de-putte, and W. J. Van-venrooij, Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies, J Clin Invest, vol.101, pp.273-281, 1998.

W. J. Van-venrooij and G. J. Pruijn, Citrullination: A small change for a protein with great consequences for rheumatoid arthritis, Arthritis Res, vol.2, pp.249-251, 2000.

M. Simon, The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis, J Clin Invest, vol.92, pp.1387-1393, 1993.

E. Girbal-neuhauser, The epitopes targeted by the rheumatoid arthritisassociated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues, J Immunol, vol.162, pp.585-594, 1999.

E. R. Vossenaar, Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin, Arthritis Res Ther, vol.6, pp.142-150, 2004.

C. Masson-bessière, The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin, J Immunol, vol.166, pp.4177-4184, 2001.

J. A. Hill, Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule, J Immunol, vol.171, pp.538-541, 2003.

I. Auger, Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen, Arthritis Rheum, vol.52, pp.3424-3432, 2005.

F. Pratesi, Effect of rheumatoid arthritis (RA) susceptibility genes on the immune response to viral citrullinated peptides in RA, J Rheumatol, vol.39, pp.1490-1493, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02084407

J. Sidney, Citrullination only infrequently impacts peptide binding to HLA class II MHC, PLoS One, vol.12, p.177140, 2017.

I. Auger, New autoantigens in rheumatoid arthritis (RA): Screening 8268 protein arrays with sera from patients with RA, Ann Rheum Dis, vol.68, pp.591-594, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02440912

G. Widera and R. A. Flavell, The nucleotide sequence of the murine I-E ? b immune response gene: Evidence for gene conversion events in class II genes of the major histocompatibility complex, EMBO J, vol.3, pp.1221-1225, 1984.

H. J. Heiniger, B. A. Taylor, E. J. Hards, and H. Meier, Heritability of the phytohemagglutinin responsiveness of lymphocytes and its relationship to leukemogenesis, Cancer Res, vol.35, pp.825-831, 1975.

Y. Takizawa, Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis, Scand J Rheumatol, vol.34, pp.212-215, 2005.

E. B. Roth, P. Stenberg, C. Book, and K. Sjöberg, Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis-New pathways to epitope spreading, Clin Exp Rheumatol, vol.24, pp.12-18, 2006.

E. H. Halvorsen, Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity, Ann Rheum Dis, vol.67, pp.414-417, 2008.

J. Zhao, Y. Zhao, J. He, R. Jia, and Z. Li, Prevalence and significance of antipeptidylarginine deiminase 4 antibodies in rheumatoid arthritis, J Rheumatol, vol.35, pp.969-974, 2008.

I. Auger, M. Martin, N. Balandraud, and J. Roudier, RA specific autoantibodies to PAD4 inhibit citrullination of fibrinogen, Arthritis Rheum, vol.62, pp.126-131, 2010.

J. R. Kolfenbach, Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis, Arthritis Rheum, vol.62, pp.2633-2639, 2010.

S. Pollmann, Anti-PAD4 autoantibodies in rheumatoid arthritis: Levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate, Rheumatol Int, vol.32, pp.1271-1276, 2012.

C. Foulquier, Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation, Arthritis Rheum, vol.56, pp.3541-3553, 2007.

S. Koushik, PAD4: Pathophysiology, current therapeutics and future perspective in rheumatoid arthritis, Expert Opin Ther Targets, vol.21, pp.433-447, 2017.

A. Suzuki, Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis, Nat Genet, vol.34, pp.395-402, 2003.

S. Raychaudhuri, Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis, Nat Genet, vol.44, pp.291-296, 2012.

K. Kim, Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis, Arthritis Rheumatol, vol.67, pp.2611-2623, 2015.

F. Anquetil, C. Clavel, G. Offer, G. Serre, and M. Sebbag, IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor-and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies, J Immunol, vol.194, pp.3664-3674, 2015.

T. Porstmann, T. Ternynck, and S. Avrameas, Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: An enzyme immunoassay for the assessment of the lymphoid cell proliferative response, J Immunol Methods, vol.82, pp.169-179, 1985.